Učitavanje...
Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab
Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease. We report an extremely rare possible s...
Spremljeno u:
| Izdano u: | Cureus |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Cureus
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8260193/ https://ncbi.nlm.nih.gov/pubmed/34262805 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.15467 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|